NEU.AXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 7月 2024 @ 15:10):
Our systems believe the stock currently is undervalued by 0.26% compare to its pairs and should correct upwards.

Stats
本日の出来高	307 770
平均出来高	420 507
時価総額	2.58B
EPS	$0.860 ( Q4 \| 2023-12-31 )
次の収益日	( $0 ) 2024-07-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	16.84 (Sector) 0 (Industry) 0
ATR14	$0.0170 (0.08%)

ACW.AX 4.84%

ADO.AX 5.00%

AGH.AX 4.35%

ANP.AX -4.92%

ATH.AX 25.00%

AVE.AX -33.33%

BIT.AX 2.63%

BNO.AX -10.00%

BOT.AX -8.70%

CAN.AX 7.14%

CPH.AX 0.00%

CSL.AX -0.88%

CTE.AX 0.81%

CUV.AX -0.65%

CYP.AX 0.00%

DXB.AX 3.92%

ECS.AX 5.88%

EOF.AX -6.67%

GSS.AX 5.56%

IDT.AX -4.55%

IMC.AX -5.68%

IMM.AX 5.08%

IMU.AX -3.51%

IXC.AX 0.00%

KZA.AX 9.59%

LCT.AX 7.14%

LGP.AX 5.26%

MSB.AX 1.01%

MVP.AX -2.47%

MXC.AX 2.44%

NEU.AX -4.98%

NOX.AX 0.00%

NSB.AX 0.00%

OCC.AX 2.82%

OPT.AX -1.43%

OSL.AX 25.00%

PAA.AX 0.00%

PAB.AX 14.29%

PAR.AX 13.73%

PBP.AX 0.00%

PIQ.AX -1.14%

PTX.AX 5.26%

PXS.AX 3.70%

PYC.AX 0.00%

RAC.AX -0.27%

RCE.AX 5.26%

SPL.AX -3.16%

TLX.AX -3.00%

VBS.AX -1.30%

相関 (AI algo v.1.1b): Undervalued: 0.26% $20.31 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.02 (neutral)

短: 0.36 (neutral)

Signal:(43.663) Neutral

Neuren Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Neuren Pharmaceuticals 相関 - 通貨/商品

0.55
( weak )

0.53
( weak )

0.00
( neutral )

0.61
( weak )

0.00
( neutral )

0.19
( neutral )

Neuren Pharmaceuticals 財務諸表

Annual	2023
収益:	$231.93M
総利益:	$205.17M (88.47 %)
EPS:	$1.240

FY	2023
収益:	$231.93M
総利益:	$205.17M (88.47 %)
EPS:	$1.240

FY	2022
収益:	$14.55M
総利益:	$14.54M (99.93 %)
EPS:	$0.00150

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0728

Financial Reports:

No articles found.

Neuren Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.